276 related articles for article (PubMed ID: 31370810)
21. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
Brennan T; Hidle A; Doshi RH; An Q; Loharikar A; Casey R; Badiane O; Ndiaye A; Diallo A; Loko Roka J; Mejia N; Abimbola T
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A77-A84. PubMed ID: 34955325
[TBL] [Abstract][Full Text] [Related]
22. Planning for human papillomavirus (HPV) vaccination in sub-Saharan Africa: a modeling-based approach.
Tracy JK; Schluterman NH; Greene C; Sow SO; Gaff HD
Vaccine; 2014 May; 32(26):3316-22. PubMed ID: 24731734
[TBL] [Abstract][Full Text] [Related]
23. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
24. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
25. Awareness of cervical cancer and willingness to be vaccinated against human papillomavirus in Mozambican adolescent girls.
Bardají A; Mindu C; Augusto OJ; Casellas A; Cambaco O; Simbine E; Matsinhe G; Macete E; Menéndez C; Sevene E; Munguambe K
Papillomavirus Res; 2018 Jun; 5():156-162. PubMed ID: 29665430
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool.
Levin A; Yuma S; Swai E; Morgan W; Gauvreau CL; Broutet N; Yeung KHT; Hutubessy R
BMC Med; 2022 Nov; 20(1):384. PubMed ID: 36316680
[TBL] [Abstract][Full Text] [Related]
27. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
[TBL] [Abstract][Full Text] [Related]
28. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam.
Levin CE; Van Minh H; Odaga J; Rout SS; Ngoc DN; Menezes L; Araujo MA; LaMontagne DS
Bull World Health Organ; 2013 Aug; 91(8):585-92. PubMed ID: 23940406
[TBL] [Abstract][Full Text] [Related]
29. Improving skills and institutional capacity to strengthen adolescent immunisation programmes and health systems in African countries through HPV vaccine introduction.
Dochez C; Burnett RJ; Mbassi SM; Were F; Musyoki A; Trovoada D; Mphahlele MJ
Papillomavirus Res; 2017 Dec; 4():66-71. PubMed ID: 29179872
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
[TBL] [Abstract][Full Text] [Related]
31. Achieving high uptake of human papillomavirus vaccination in Malaysia through school-based vaccination programme.
Muhamad NA; Buang SN; Jaafar S; Jais R; Tan PS; Mustapha N; Lodz NA; Aris T; Sulaiman LH; Murad S
BMC Public Health; 2018 Dec; 18(1):1402. PubMed ID: 30577816
[TBL] [Abstract][Full Text] [Related]
32. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach.
Vanni T; Luz PM; Foss A; Mesa-Frias M; Legood R
Vaccine; 2012 Jul; 30(32):4866-71. PubMed ID: 22652405
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.
Aljunid S; Maimaiti N; Nur AM; Noor MRM; Wan Puteh SE
BMC Public Health; 2016 Jan; 16():71. PubMed ID: 26803814
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
Owsianka B; Gańczak M
Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
[TBL] [Abstract][Full Text] [Related]
38. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus vaccine delivery in Mozambique: identification of implementation performance drivers using the Consolidated Framework for Implementation Research (CFIR).
Soi C; Gimbel S; Chilundo B; Muchanga V; Matsinhe L; Sherr K
Implement Sci; 2018 Dec; 13(1):151. PubMed ID: 30545391
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]